Nifty Pharma recovers, Asian drugmakers shares tumble as Trump to slash US drug prices

Nifty Pharma recovers, Asian drugmakers shares tumble as Trump to slash US drug prices

Nifty Pharma recovers, Asian drugmakers shares tumble as Trump to slash US drug prices

How did your country report this? Share your view in the comments.

Introduction:

The news topic “Nifty Pharma recovers, Asian drugmakers shares tumble as Trump to slash US drug prices” has drawn international attention, with various media outlets providing diverse insights, historical context, political stances, and on-the-ground developments. Below is a curated overview of how different countries and media organizations have covered this topic recently.

Quick Summary:

  • The Nifty Pharma index was among the sole sectoral laggards in trade today. The index was mildly higher, up 0.3 percent to quote 21,138.90. Constituents such as Mankind Pharma, Dr Reddy’s and Granules India were leading the gains, rising up to four percent.Across Asia, South Korean and Japanese drugmakers’ shares plummeted. Japanese pharmaceutical stocks tumbled in early Tokyo trade, with Chugai Pharmaceutical sliding as much as 7.2 percent, its steepest drop in a month. In South Korea, shares of SK Biopharmaceuticals, Celltrion, and Samsung Biologics were down more than 3 percent. In India, the Nifty Pharmaceuticals index erased its losses, up up to 4 percent.
  • Domestic pharmaceutical and healthcare stocks reversed early losses on Monday. US President Donald Trump pledged to cut prescription drug prices in the United States, aiming to bring them in line with global standards. In contrast, pharmaceutical stocks across Asia saw sharp declines amid fears that the pricing pressure in the US could hurt margins and earnings growth. The Nifty Pharma index, which had fallen nearly 2 per cent in early trade, rebounded to edge up by 0.3 per cent to 21,138.90 by 10.45 am. In Japan, Chugai Pharmaceutical plunged as much as 7.2% in early Tokyo trade — its biggest intraday fall in a month. South Korean players including SK Biopharmaceuticals, Celltrion, and Samsung Biologics were down more than 3 per cent.
  • Nifty Pharma Rebounds As Asian Drug Stocks Slide On Trump’s Drug Price Cut Plans. Domestic pharmaceutical and healthcare stocks staged a mild recovery on Monday, May 12, after initially slipping. In contrast, Asia-based drugmakers extended their slide, with some falling as much as 7% amid concerns over future earnings growth. Japanese pharma giants such as Chugai Pharmaceutical tumbled up to 7.2%, while Daiichi Sankyo and Takeda Pharmaceutical declined by around 5% each. South Korean stocks like SK Biopharmaceuticals, Celltrion, and Samsung Biologics also dropped more than 3%. The Nifty Pharma index recovered to trade 0.3% higher at 21,138.90 by 10:45 AM on Monday.

Country-by-Country Breakdown:

Original Coverage

The Nifty Pharma index was among the sole sectoral laggards in trade today. The index was mildly higher, up 0.3 percent to quote 21,138.90. Constituents such as Mankind Pharma, Dr Reddy’s and Granules India were leading the gains, rising up to four percent.Across Asia, South Korean and Japanese drugmakers’ shares plummeted. Japanese pharmaceutical stocks tumbled in early Tokyo trade, with Chugai Pharmaceutical sliding as much as 7.2 percent, its steepest drop in a month. In South Korea, shares of SK Biopharmaceuticals, Celltrion, and Samsung Biologics were down more than 3 percent. In India, the Nifty Pharmaceuticals index erased its losses, up up to 4 percent. Read full article

Domestic Pharma Stocks Recover As Trump Vows Global Price Cuts

Domestic pharmaceutical and healthcare stocks reversed early losses on Monday. US President Donald Trump pledged to cut prescription drug prices in the United States, aiming to bring them in line with global standards. In contrast, pharmaceutical stocks across Asia saw sharp declines amid fears that the pricing pressure in the US could hurt margins and earnings growth. The Nifty Pharma index, which had fallen nearly 2 per cent in early trade, rebounded to edge up by 0.3 per cent to 21,138.90 by 10.45 am. In Japan, Chugai Pharmaceutical plunged as much as 7.2% in early Tokyo trade — its biggest intraday fall in a month. South Korean players including SK Biopharmaceuticals, Celltrion, and Samsung Biologics were down more than 3 per cent. Read full article

Nifty Pharma Rebounds As Asian Drug Stocks Slide On Trump’s Drug Price Cut Plans

Nifty Pharma Rebounds As Asian Drug Stocks Slide On Trump’s Drug Price Cut Plans. Domestic pharmaceutical and healthcare stocks staged a mild recovery on Monday, May 12, after initially slipping. In contrast, Asia-based drugmakers extended their slide, with some falling as much as 7% amid concerns over future earnings growth. Japanese pharma giants such as Chugai Pharmaceutical tumbled up to 7.2%, while Daiichi Sankyo and Takeda Pharmaceutical declined by around 5% each. South Korean stocks like SK Biopharmaceuticals, Celltrion, and Samsung Biologics also dropped more than 3%. The Nifty Pharma index recovered to trade 0.3% higher at 21,138.90 by 10:45 AM on Monday. Read full article

Why generic pharma may dodge hit even as Trump revives drug pricing order

The Nifty Pharma index was the only sectoral index that opened in the red, amid an across-the-board rally. Trump said he would sign executive orders aimed at slashing US drug prices by 30–80% by pegging them to the lowest prices paid globally. The plan is expected to be formalised on May 12 at 9 AM and is centered around a ‘Most Favoured Nation’ (MFN) pricing model. This would benchmark US drug Prices to those in countries paying the least. The policy is likely to face legal pushback from the pharmaceutical industry, as it did in late 2020 when courts blocked its implementation citing violations of the Administrative Procedure Act. The Biden administration ultimately withdrew the rule in December 2021. For now, Indian generic companies appear largely insulated. A 2024 report by the US Department of Health and Human Services showed that while US brand drug prices are more than four times higher than international averages, generics are actually 33% cheaper than in peer countries. Read full article

Stock Market Highlights: Sensex falls 322 pts, Nifty below 23,300 after Trump imposes 26% tariffs – The Economic Times

Indias benchmark indexes traded lower on Thursday following U.S. President Donald Trumps imposition of a 26% reciprocal tariff on imports from the South Asian country. Sensex Today | Stock Market Highlights | Indias benchmark index traded lower following US-China trade tensions. New: Dollar gains versus yen on US- China trade optimism; Kiwi climbs 52W – High 52w – Low. Read full article

Global Perspectives Summary:

Global media portray this story through varied cultural, economic, and political filters. While some focus on geopolitical ramifications, others highlight local impacts and human stories. Some nations frame the story around diplomatic tensions and international relations, while others examine domestic implications, public sentiment, or humanitarian concerns. This diversity of coverage reflects how national perspectives, media freedom, and journalistic priorities influence what the public learns about global events.

How did your country report this? Share your view in the comments.

Sources:

Source: https://www.moneycontrol.com/news/business/markets/nifty-pharma-recovers-asian-drugmakers-shares-tumble-as-trump-to-slash-us-drug-prices-13020615.html

Leave a Reply

Your email address will not be published. Required fields are marked *